Cytokinetics and Astellas Announce New Phase 2 Clinical Trial
Cytokinetics and Astellas jointly announced plans to begin a Phase 2 clinical trial in 2015 in patients with spinal muscular atrophy. The trial will test CK-2127107, a muscle activator. CK-2127107 will be the seventh SMA drug program to advance to clinical trials. Cure SMA provided funding to Cytokinetics for research focused on the potential application […]
Cytokinetics and Astellas Announce New Phase 2 Clinical Trial Read More »








